| Revision as of 12:46, 15 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').← Previous edit |
Latest revision as of 02:52, 19 December 2024 edit undoCarlstak (talk | contribs)Extended confirmed users35,916 edits →Mechanism of action: ce |
| (270 intermediate revisions by more than 100 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Anti-inflammatory drug}} |
|
{{Drugbox |
|
|
|
{{Use dmy dates|date=January 2024}} |
|
|
{{cs1 config |name-list-style=vanc |display-authors=6}} |
|
|
{{Infobox drug |
|
| Watchedfields = changed |
|
| Watchedfields = changed |
|
| verifiedrevid = 443873618 |
|
| verifiedrevid = 460769466 |
|
|
| image = Indometacin.svg |
|
| IUPAC_name = 2-{1--5-methoxy-2-methyl-1''H''-indol-3-yl}acetic acid |
|
|
|
| width = 225 |
|
| image = Indometacin skeletal.svg |
|
|
| width = 220 |
|
| alt = |
|
|
| image2 = Indometacin-from-xtal-2003-ball-and-stick.png |
|
|
| alt2 = |
|
|
| USAN = Indomethacin |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
|
| pronounce = {{IPAc-en|ɪ|n|d|oʊ-|ˈ|m|ɛ|t|ə|s|ᵻ|n}} |
|
| tradename = |
|
|
|
| tradename = Indocid, Indocin |
|
| Drugs.com = {{drugs.com|international|indometacin}} |
|
|
|
| DailyMedID = Indomethacin |
|
| pregnancy_category = C <small>(])</small>, C/D <small>]</small> |
|
|
|
| Drugs.com = {{drugs.com|monograph|indomethacin}} |
|
| legal_status = Rx-only |
|
|
|
| pregnancy_AU = C |
|
| routes_of_administration = Oral, ], ], topical |
|
|
|
| pregnancy_category = |
|
|
| routes_of_administration = ], ], ], ] |
|
|
| ATC_prefix = C01 |
|
|
| ATC_suffix = EB03 |
|
|
| ATC_supplemental = {{ATC|M01|AB01}}, {{ATC|M02|AA23}}, {{ATC|S01|BC01}} |
|
|
|
|
|
| legal_AU = Schedule 4 |
|
|
| legal_CA = Rx-only |
|
|
| legal_UK = POM |
|
|
| legal_US = Rx-only |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| bioavailability = ~100% (oral), 80–90% (rectal) |
|
| bioavailability = ~100% (oral), 80–90% (rectal) |
|
| protein_bound = 99% |
|
| protein_bound = 99%<ref name = MD/> |
|
| metabolism = ] |
|
| metabolism = ] |
|
| elimination_half-life = 4.5 hours |
|
| elimination_half-life = 2.6-11.2 hours (adults), 12-28 hours (infants)<ref name = MD/> |
|
| excretion = ] 60%, ] 33% |
|
| excretion = ] (60%), ] (33%) |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 53-86-1 |
|
| CAS_number = 53-86-1 |
|
| ATC_prefix = C01 |
|
|
| ATC_suffix = EB03 |
|
|
| ATC_supplemental = {{ATC|M01|AB01}}, {{ATC|M02|AA23}}, {{ATC|S01|BC01}} |
|
|
| PubChem = 3715 |
|
| PubChem = 3715 |
|
| IUPHAR_ligand = 1909 |
|
| IUPHAR_ligand = 1909 |
| Line 41: |
Line 53: |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL = 6 |
|
| ChEMBL = 6 |
|
|
| PDB_ligand = IMN |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
|
| IUPAC_name = 2-<nowiki/>{1--5-methoxy-2-methyl-1''H''-indol-3-yl}acetic acid |
|
| C=19 | H=16 | Cl=1 | N=1 | O=4 |
|
|
|
| C=19 | H=16 | Cl=1 | N=1 | O=4 |
|
| molecular_weight = 357.787 g.mol<sup>-1</sup> |
|
|
| smiles = Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O |
|
| SMILES = Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O |
|
| InChI = 1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) |
|
|
| InChIKey = CGIGDMFJXJATDK-UHFFFAOYAA |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) |
|
| StdInChI = 1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = CGIGDMFJXJATDK-UHFFFAOYSA-N |
|
| StdInChIKey = CGIGDMFJXJATDK-UHFFFAOYSA-N |
|
|
}} |
|
}}<!--Please do not change "indometacin" to "indomethacin". "Indometacin" is not a typo, it is the International Nonproprietary Name.--> |
|
|
'''Indometacin''' (]) or '''indomethacin''' (] and former ]) is a ] commonly used to reduce ], ], stiffness, and ]. It works by inhibiting the production of ]s, molecules known to cause these symptoms. It is marketed under many trade names, including '''Indocin''', '''Indocid''', '''Indochron E-R''', and '''Indocin-SR'''. |
|
|
|
|
|
|
|
<!-- Please do not change "indometacin" to "indomethacin". "Indometacin" is not a typo, it is the International Nonproprietary Name. --> |
|
== Indications == |
|
|
|
'''Indometacin''', also known as '''indomethacin''', is a ] (NSAID) commonly used as a ] to reduce ], ], ], and ] from ]. It works by inhibiting the production of ]s, ] ]s known to cause these symptoms. It does this by inhibiting ], an ] that ] the production of prostaglandins.<ref name = MD>{{cite web|title=Indometacin|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=14 January 2014|access-date=22 June 2014|url= http://www.medicinescomplete.com/mc/martindale/current/ms-2658-m.htm| veditors = Brayfield A |location=London, UK}}</ref><ref>{{cite web | title=TGA Approved Terminology for Medicines, Section 1 – Chemical Substances | date=July 1999 | publisher=Therapeutic Goods Administration, Department of Health and Ageing, Australian Government | page=70 | url=http://www.tga.gov.au/pdf/medicines-approved-terminology-chemical.pdf }}</ref> |
|
{{Ref improve section|date=December 2010}} |
|
|
Clinical indications for indometacin include: |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] (menstrual cramps) |
|
|
* ] |
|
|
* ] and ] associated with malignant diseases (especially tumor fever associated with liver involvement, lymphogranulomatosis) |
|
|
* ] |
|
|
* ] (prostaglandin inhibits ]'s action in the ]) |
|
|
* ] |
|
|
* ] |
|
|
* ], ] and ] |
|
|
* ]<ref name="pmid15327584">{{cite journal |author=Smyth JM |title=Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study |journal=Br J Clin Pharmacol |volume=58 |issue=3 |pages=249–58 |year=2004 |month=September |pmid=15327584 |pmc=1884560 |doi=10.1111/j.1365-2125.2004.02139.x |url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0306-5251&date=2004&volume=58&issue=3&spage=249 |author-separator=, |author2=Collier PS |author3=Darwish M |display-authors=3 |last4=Millership |first4=J. S. |last5=Halliday |first5=H. L. |last6=Petersen |first6=S. |last7=McElnay |first7=J. C.}}</ref> |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] (pain due to ]) |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
|
|
|
|
|
It was patented in 1961 and approved for medical use in 1963.<ref>{{cite journal | vauthors = Hart FD, Boardman PL | title = Indomethacin: A New Non-steroid Anti-inflammatory Agent | journal = British Medical Journal | volume = 2 | issue = 5363 | pages = 965–970 | date = October 1963 | pmid = 14056924 | pmc = 1873102 | doi = 10.1136/bmj.2.5363.965 }}</ref><ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=517 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA517 |language=en}}</ref> It is on the ].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Indomethacin Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Indomethacin | access-date = 30 August 2024 }}</ref> |
|
Indomethacin has also been used clinically to delay ], reduce ] in ], and to close ]. |
|
|
|
|
|
|
|
==Medical uses== |
|
Indomethacin is a potent drug with many serious side effects and should not be considered an analgesic for minor aches and pains or fever. The drug is more potent than ], but is not a better analgesic.{{Citation needed|date=January 2011}} In mild to moderate ] a standard oral dose (25mg/50mg/75mg ?) of indomethacin proved as effective as 600 mg aspirin.{{Citation needed|date=January 2011}} The drug is best used as an anti-inflammatory, rather than an analgesic. |
|
|
|
As an NSAID, indometacin is an ], ], and ]. Clinical indications for indometacin include:<br> |
|
|
'''Joint diseases''' |
|
|
*]<ref name="Lucas 2016">{{cite journal | vauthors = Lucas S | title = The Pharmacology of Indomethacin | journal = Headache | volume = 56 | issue = 2 | pages = 436–446 | date = February 2016 | pmid = 26865183 | doi = 10.1111/head.12769 | s2cid = 205160729 }}</ref> |
|
|
*]<ref name="Lucas 2016"/> |
|
|
*]<ref name="Lucas 2016"/> |
|
|
*]<ref name="Lucas 2016"/> |
|
|
*acute painful shoulder ] or ]<ref name="Lucas 2016"/> |
|
|
'''Headaches''' |
|
|
*]s<ref name="Dodick 2004">{{cite journal | vauthors = Dodick DW | title = Indomethacin-responsive headache syndromes | journal = Current Pain and Headache Reports | volume = 8 | issue = 1 | pages = 19–26 | date = February 2004 | pmid = 14731379 | doi = 10.1007/s11916-004-0036-6 | s2cid = 24393617 }}</ref> |
|
|
*]s<ref name="Dodick 2004"/> |
|
|
*Chronic paroxysmal hemicrania<ref name="Dodick 2004"/> |
|
|
*Episodic paroxysmal hemicrania<ref name="Dodick 2004"/> |
|
|
*]<ref name="Dodick 2004"/> |
|
|
*Valsalva-induced headaches<ref name="Dodick 2004"/> |
|
|
*Primary cough headache<ref name="Dodick 2004"/> |
|
|
*Primary exertional headache<ref name="Dodick 2004"/> |
|
|
*Primary headache associated with sexual activity (preorgasmic and orgasmic)<ref name="Dodick 2004"/> |
|
|
*Primary stabbing headache (jabs and jolts syndrome)<ref name="Dodick 2004"/> |
|
|
*]<ref name="Dodick 2004"/> |
|
|
'''Others''' |
|
|
*]<ref>{{cite journal | vauthors = Sekar KC, Corff KE | title = Treatment of patent ductus arteriosus: indomethacin or ibuprofen? | journal = Journal of Perinatology | volume = 28 | issue = Suppl 1 | pages = S60–S62 | date = May 2008 | pmid = 18446180 | doi = 10.1038/jp.2008.52 | doi-access = | s2cid = 5553768 }}</ref> |
|
|
|
|
|
== Contraindications == |
|
==Contraindications== |
|
* concurrent ], or history of ulcer disease |
|
* Concurrent ], or history of ulcer disease |
|
* allergy to indomethacin, aspirin, or other NSAIDs |
|
* Allergy to indometacin, aspirin, or other NSAIDs |
|
* patients with nasal ] reacting with an ] to other NSAIDs |
|
* ] gastric bypass and ] patients |
|
|
* Patients with nasal ] reacting with an ] to other NSAIDs |
|
|
* Children under 2 years of age (with the exception of neonates with ]) |
|
|
* Severe pre-existing renal and liver damage |
|
|
* Caution: pre-existing bone marrow damage (frequent blood cell counts are indicated) |
|
|
* Caution: bleeding tendencies of unknown origin (indometacin inhibits ] aggregation) |
|
|
* Caution: ], ], psychotic disorders (indometacin may worsen these conditions)<ref>{{cite web|title=INDOMETHACIN|url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+53-86-1|work=Hazardous Substances Data Bank (HSDB)|publisher=National Library of Medicine's TOXNET|access-date=4 April 2013}}</ref> |
|
|
* Concurrent with potassium sparing diuretics |
|
|
* Patients who have a ] dependent heart defect (such as ]) |
|
|
* Significant ] (high blood pressure) |
|
|
* Concomitant administration of ] (such as lithium carbonate) |
|
|
|
|
|
|
==Adverse effects== |
|
* children under 2 years of age (with the exception of neonates with patent ductus arteriosus) |
|
|
|
{{see also|Nonsteroidal anti-inflammatory drug}} |
|
* severe pre-existing renal and liver damage |
|
|
|
In general, the adverse effects of indometacin are similar to those of all other NSAIDs. For instance, indometacin inhibits both ] and ], which then inhibits the production of ]s in the ] and ] responsible for maintaining the ] of the ]. Indometacin, therefore, like other non-selective COX inhibitors, can cause ]s. These ulcers can result in serious bleeding or perforation, requiring hospitalization of the patient. |
|
* caution: pre-existing bone marrow damage (frequent blood cell counts are indicated) |
|
|
* caution: bleeding tendencies of unknown origin (indomethacin inhibits ] aggregation) |
|
|
* caution: ]<ref>National Institute of Health </ref>, ], psychotic disorders (indomethacin may worsen these conditions) |
|
|
* concurrent with potassium sparing diuretics |
|
|
* patients who have a ] dependent heart defect (such as ]) |
|
|
* significant ] (high blood pressure) |
|
|
|
|
|
|
|
To reduce the possibility of peptic ulcers, indometacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50 and 200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ] 150 mg at bedtime, or ] 20 mg at bedtime). Other common gastrointestinal complaints, including ], ] and mild ] are less serious and rarely require discontinuation of indometacin. |
|
== Mechanism of action == |
|
|
{{main|Non-steroidal anti-inflammatory drug}} |
|
|
|
|
|
|
|
Many NSAIDs, but particularly indometacin, cause ] retention by reducing its excretion by the ]s. Thus indometacin users have an elevated risk of lithium toxicity. For patients taking lithium (e.g. for treatment of ] or ]), less toxic NSAIDs such as ] or ] are preferred. |
|
Indomethacin is a nonselective inhibitor of ] (COX) 1 and 2, enzymes that participate in prostaglandin synthesis from ]. Prostaglandins are ]-like molecules normally found in the body, where they have a wide variety of effects, some of which lead to pain, fever, and inflammation. |
|
|
|
|
|
|
|
All NSAIDs, including indometacin, also increase ] and ] levels, and increase ] and ] retention. ] activity is also enhanced. Together these may lead to: |
|
Prostaglandins also cause ]s in pregnant women. Indomethacin is an effective ],<ref name="pmid17459777">{{cite journal |author=Giles W, Bisits A |title=Preterm labour. The present and future of tocolysis |journal=Best Pract Res Clin Obstet Gynaecol |volume=21 |issue=5 |pages=857–68 |year=2007 |month=October |pmid=17459777 |doi=10.1016/j.bpobgyn.2007.03.011 |url=}}</ref> able to delay premature labor by reducing uterine contractions through inhibition of PG synthesis in the uterus and possibly through ] blockade. |
|
|
|
|
|
|
|
* ] (swelling due to fluid retention) |
|
Indomethacin has two additional modes of actions with clinical importance: |
|
|
|
* ] (high potassium levels)<ref>{{cite journal | vauthors = Akbarpour F, Afrasiabi A, Vaziri ND | title = Severe hyperkalemia caused by indomethacin and potassium supplementation | journal = Southern Medical Journal | volume = 78 | issue = 6 | pages = 756–757 | date = June 1985 | pmid = 4002013 | doi = 10.1097/00007611-198506000-00039 }}</ref> |
|
* It inhibits motility of polymorphonuclear leukocytes, similar to ]. |
|
|
|
* ] (high sodium levels) |
|
* It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, like salicylates. |
|
|
|
* ] |
|
These additional effects account as well for the analgesic and the anti-inflammatory properties. |
|
|
|
|
|
|
|
Elevations of serum ] and more serious renal damage such as acute ], chronic ] and ], are also possible. These conditions also often begin with edema and ]. |
|
Indomethacin readily crosses the ] and can reduce ] ] production to treat ]. It does so by reducing renal blood flow and increasing renal vascular resistance, possibly by enhancing the effects of ] on the fetal kidneys. |
|
|
|
|
|
|
|
Paradoxically yet uncommonly, indometacin can cause headache (10 to 20%), sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal damage). There are unsubstantiated reports of worsening Parkinson's disease, epilepsy, and psychiatric disorders. Cases of life-threatening shock (including ], sweating, severe ] and ] as well as acute ]), severe or lethal ] and severe bone marrow damage have all been reported. Skin reactions and ] are also possible side effects. |
|
== Adverse effects == |
|
|
Since indomethacin inhibits both ] and ], it inhibits the production of prostaglandins in the ] and ], which maintain the ] of the ]. Indomethacin, therefore, like other non-selective COX inhibitors can cause ]s. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. |
|
|
|
|
|
|
|
The frequency and severity of side effects and the availability of better tolerated alternatives make indometacin today a drug of second choice. Its use in acute ] attacks and in ] is well-established because in these indications the duration of treatment is limited to a few days only, therefore serious side effects are not likely to occur. |
|
To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ] 150 mg at bedtime, or ] 20 mg at bedtime). Other common gastrointestinal complaints, including ], ] and mild ] are less serious and rarely require discontinuation of indomethacin. |
|
|
|
|
|
|
|
People should undergo regular physical examination to detect edema and signs of central nervous side effects. Blood pressure checks will reveal development of hypertension. Periodic serum electrolyte (sodium, potassium, chloride) measurements, complete blood cell counts and assessment of liver enzymes as well as of creatinine (renal function) should be performed. This is particularly important if Indometacin is given together with an ] or with potassium-sparing ]s, because these combinations can lead to ] and/or serious kidney failure. No examinations are necessary if only the topical preparations (spray or gel) are applied. |
|
Many NSAIDs, but particularly indomethacin, cause ] retention by reducing its excretion by the ]s. Thus indomethacin users have an elevated risk of lithium toxicity. For patients taking lithium (e.g. for treatment of ] or ]), less toxic NSAIDs such as ] or ], are preferred. |
|
|
|
|
|
|
|
Rare cases have shown that use of this medication by pregnant women can have an effect on the fetal heart, possibly resulting in fetal death via premature closing of the ].<ref>{{cite journal | vauthors = Enzensberger C, Wienhard J, Weichert J, Kawecki A, Degenhardt J, Vogel M, Axt-Fliedner R | title = Idiopathic constriction of the fetal ductus arteriosus: three cases and review of the literature | journal = Journal of Ultrasound in Medicine | volume = 31 | issue = 8 | pages = 1285–1291 | date = August 2012 | pmid = 22837295 | doi = 10.7863/jum.2012.31.8.1285 | s2cid = 6798504 }}{{dead link|date=December 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> |
|
Indomethacin also reduces ] and ] levels, and increases ] and ] retention. It also enhances the effects of ]. Together these may lead to: |
|
|
|
|
|
|
|
In October 2020, the U.S. ] (FDA) required the ] to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.<ref name="FDA PR 20201015" /><ref name="FDA safety 20201015" /> They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.<ref name="FDA PR 20201015">{{cite press release | title=FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications | website=U.S. ] (FDA) | date=15 October 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-warns-using-type-pain-and-fever-medication-second-half-pregnancy-could-lead-complications | access-date=15 October 2020}} {{PD-notice}}</ref><ref name="FDA safety 20201015">{{cite web | title=NSAIDs may cause rare kidney problems in unborn babies | website=U.S. Food and Drug Administration | date=21 July 2017 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic | access-date=15 October 2020}} {{PD-notice}}</ref> |
|
* ] (swelling due to fluid retention) |
|
|
* ] (high potassium levels)<ref>{{cite journal | author = Akbarpour F, Afrasiabi A, Vaziri N | title = Severe hyperkalemia caused by indomethacin and potassium supplementation | journal = South Med J | volume = 78 | issue = 6 | pages = 756–7 | year = 1985 | pmid = 4002013 | doi = 10.1097/00007611-198506000-00039}}</ref> |
|
|
* ] (high sodium levels) |
|
|
* hypertension |
|
|
|
|
|
|
|
==Mechanism of action== |
|
The drug may also cause elevations of serum ] and more serious renal damage such as acute renal failure, chronic ] and ]. These conditions also often begin with edema and hyperkalemia. |
|
|
|
{{Main|Non-steroidal anti-inflammatory drug}} |
|
|
|
|
|
|
Indometacin, a non-steroidal anti-inflammatory drug (NSAID), has similar mode of action when compared to other drugs in this group. It is a nonselective inhibitor of ] (COX) 1 and 2, the enzymes that participate in ] ] from ]. Prostaglandins are ]-like molecules normally found in the body, where they have a wide variety of effects, some of which lead to pain, fever, and inflammation. By inhibiting the synthesis of prostaglandins, indometacin can reduce pain, fever, and inflammation.<ref name="Lucas 2016"/> Mechanism of action of indomethacin, along with several other NSAIDs that inhibit COX, was described in 1971.<ref>{{cite journal | vauthors = Ferreira SH, Moncada S, Vane JR | title = Indomethacin and aspirin abolish prostaglandin release from the spleen | journal = Nature | volume = 231 | issue = 25 | pages = 237–239 | date = June 1971 | pmid = 5284362 | doi = 10.1038/newbio231237a0 }}</ref> |
|
Additionally, indomethacin quite often causes headache (10 to 20%), sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal damage). There were reports of worsening Parkinson's disease, epilepsy, and psychiatric disorders but these are not substantiated. Cases of life-threatening shock (including ], sweating, severe ] and ] as well as acute ]), severe or lethal ] and severe bone marrow damage have all been reported. Skin reactions and ] are also possible side effects. |
|
|
|
|
|
|
|
Additionally, indometacin has recently been found to be a ] of the ]. By enhancing the ] and signalling of ] such as ], PAMs may elicit increased cannabinergic signalling in a ], reducing the incidence of problematic side effects such as ] while maintaining some ] activity.<ref>{{cite journal | vauthors = Laprairie RB, Mohamed KA, Zagzoog A, Kelly ME, Stevenson LA, Pertwee R, Denovan-Wright EM, Thakur GA | title = Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling | journal = Frontiers in Molecular Neuroscience | volume = 12 | pages = 257 | date = 18 October 2019 | pmid = 31680861 | pmc = 6813218 | doi = 10.3389/fnmol.2019.00257 | doi-access = free }}</ref> |
|
Due to its strong ] activity indomethacin may obscure the clinical course of serious infections. |
|
|
|
|
|
|
|
Indometacin has a logarithmic ] of 3 to 4.5. Since the physiologic body pH is well above the pKa range of indometacin, most of the indometacin molecules will be dissociated into ionized form, leaving very little un-ionized form of indometacin to cross a cell membrane. If the pH gradient across a cell membrane is high, most of the indometacin molecules will be trapped in one side of the membrane with higher pH. This phenomenon is called "ion trapping". The phenomenon of ion trapping is particularly prominent in the stomach as pH at the stomach mucosa layer is extremely acidic, while the ]s are more alkaline. Therefore, indometacin are trapped inside the parietal cells in ionized form, damaging the stomach cells, causing stomach irritation. This stomach irritation can reduce if the stomach acidity is reduced, as the GI side effects from NSAIDs are generally reduced by decreasing stomach acidity.<ref name="Lucas 2016"/> |
|
] has also been reported with prolonged use. |
|
|
|
|
|
|
|
Indometacin's role in treating certain headaches is unique compared to other NSAIDs. In addition to the class effect of COX inhibition, there is evidence that indometacin has the ability to reduce cerebral blood flow not only through modulation of nitric oxide pathways but also via intracranial precapillary vasoconstriction.<ref name="pmid9876886">{{cite journal | vauthors = Castellano AE, Micieli G, Bellantonio P, Buzzi MG, Marcheselli S, Pompeo F, Rossi F, Nappi G | title = Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications | journal = Cephalalgia | volume = 18 | issue = 9 | pages = 622–630 | date = November 1998 | pmid = 9876886 | doi = 10.1046/j.1468-2982.1998.1809622.x }}</ref> The indometacin property of reducing cerebral blood flow is useful in treating raised intracranial pressure. A case report has shown that an intravenous bolus dose of indometacin given with 2 hours of continuous infusion is able to reduce intracranial pressure by 37% in 10 to 15 minutes and increases cerebral perfusion pressure by 30% at the same time.<ref name="Lucas 2016"/> This reduction in cerebral pressure may be responsible for the remarkable efficacy in a group of headaches that is referred to as "indometacin-responsive headaches", such as idiopathic stabbing headache, chronic paroxysmal hemicranial, and exertional headaches.<ref>{{cite book | vauthors = Dowd FJ, Johnson B, Mariotti A | chapter = Chapter 23, Drugs for Treating Orofacial Pain Syndromes. | pages = 384–385 | title = Pharmacology and Therapeutics for Dentistry-E-Book. Elsevier Health Sciences; 2016 Sep 3. }}</ref> On the other hand, the activation of ] in the ] is used to stimulate the trigeminal autonomic reflex arc, causing a type of headache called ]. Indometacin inhibits the superior salivatory nucleus, thus relieving this type of headache.<ref name="Lucas 2016"/> |
|
The frequency and severity of side effects and the availability of better tolerated alternatives make indomethacin today a drug of second choice. Its use in acute ] attacks and in ] is well-established because in these indications the duration of treatment is limited to a few days only, therefore serious side effects are not likely to occur. |
|
|
|
|
|
|
|
Prostaglandins also cause ]s in pregnant women. Indometacin is an effective ],<ref name="pmid17459777">{{cite journal | vauthors = Giles W, Bisits A | title = Preterm labour. The present and future of tocolysis | journal = Best Practice & Research. Clinical Obstetrics & Gynaecology | volume = 21 | issue = 5 | pages = 857–868 | date = October 2007 | pmid = 17459777 | doi = 10.1016/j.bpobgyn.2007.03.011 }}</ref> able to delay premature labor by reducing uterine contractions through inhibition of prostaglandin synthesis in the uterus and possibly through ] blockade. |
|
== Necessary examinations during long term treatment == |
|
|
|
|
|
|
|
Indometacin readily crosses the ] and can reduce ] ] production to treat ]. It does so by reducing renal blood flow and increasing renal vascular resistance, possibly by enhancing the effects of ] on the fetal kidneys. |
|
Patients should undergo regular physical examination to detect edema and signs of central nervous side effects. Blood pressure checks will reveal development of hypertension. Periodic serum electrolyte (sodium, potassium, chloride) measurements, complete blood cell counts and assessment of liver enzymes as well as of creatinine (renal function) should be performed. This is particularly important if Indomethacin is given together with an ] or with potassium-sparing ]s, because these combinations can lead to hyperkalemia and/or serious kidney failure. No examinations are necessary if only the topical preparations (spray or gel) are applied. |
|
|
|
|
|
|
|
Other modes of action for indometacin are: |
|
== Animal toxicity and human overdose == |
|
|
|
* it inhibits motility of polymorphonuclear leukocytes, similar to ] |
|
|
* it uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, like salicylates |
|
|
* it has been found to specifically inhibit MRP (multidrug resistance proteins) in murine and human cells<ref name="pmid9062400">{{cite journal | vauthors = Draper MP, Martell RL, Levy SB | title = Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein | journal = British Journal of Cancer | volume = 75 | issue = 6 | pages = 810–815 | date = 1997 | pmid = 9062400 | pmc = 2063393 | doi = 10.1038/bjc.1997.145 }}</ref> |
|
|
|
|
|
|
==Nomenclature== |
|
Indomethacin has a high acute toxicity both for animals (12 mg/kg in rats and 50 mg/kg in mice) and for humans. Exact human data does not exist, but some fatal human cases, particularly in children and adolescents, have been seen. |
|
|
|
Indometacin is the {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}} of the drug while indomethacin is the {{abbrlink|USAN|United States Approved Name}}, and former {{abbrlink|AAN|Australian Approved Name}} and {{abbrlink|BAN|British Approved Name}}.<ref name="Elks2014">{{cite book | vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA684|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|page=684}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA550|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|page=550}}</ref><ref name="MortonHall2012">{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA153|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|page=153}}</ref> |
|
|
|
|
Generally, overdose in humans causes drowsiness, dizziness, severe headache, mental confusion, ], numbness of limbs, nausea and vomiting. Severe gastrointestinal bleeding is also possible. Cerebral edema, and cardiac arrest with fatal outcome have been seen in children. |
|
|
|
|
|
The treatment is symptomatic and largely the same as with ]. However, the possibility of severe GI tract symptoms should be particularly noted. |
|
|
|
|
|
The risk of overdose after exaggerated local treatment with gel or spray is very limited. |
|
|
|
|
|
== Usual dosage forms == |
|
|
|
|
|
* tablets or capsules 25 and 50 mg |
|
|
* suppositories 50 and 100 mg |
|
|
* modified-release Capsules 75 mg |
|
|
* syrup (25 mg/5ml) |
|
|
* injectable concentrate 50 mg for i.m. injection |
|
|
* spray or gel |
|
|
* patches containing 0.5% by weight |
|
|
* 1% topical liquid |
|
|
|
|
|
== History == |
|
|
Indomethacin was discovered in 1963<ref>{{cite journal | author = Hart F, Boardman P | title = Indomethacin: A New Non-steroid Anti-inflammatory Agent | journal = Br Med J | volume = 5363 | issue = 5363| pages = 965–70 | year = 1963 | month=October | pmid = 14056924 | doi = 10.1136/bmj.2.5363.965 | pmc = 1873102}}</ref> and it was first approved for use in the U.S. by the ] in 1965. Its mechanism of action, along with several other NSAIDs that inhibit COX, was described in 1971.<ref>{{cite journal | author = Ferreira S, Moncada S, Vane J | title = Indomethacin and aspirin abolish prostaglandin release from the spleen | journal = Nat New Biol | volume = 231 | issue = 25 | pages = 237–9 | year = 1971 | month=Jun 23 | pmid = 5284362 | doi = 10.1038/231237a0}}</ref> |
|
|
|
|
|
|
== References == |
|
== References == |
|
{{reflist|2}} |
|
{{Reflist}} |
|
|
|
|
|
== External links == |
|
|
* , academic dissertation (]) |
|
|
* |
|
|
* |
|
|
* , from RxList.com |
|
|
{{-}} |
|
|
{{NSAIDs}} |
|
|
{{Anti-inflammatory and antirheumatic products}} |
|
{{Anti-inflammatory and antirheumatic products}} |
|
{{Topical products for joint and muscular pain}} |
|
{{Topical products for joint and muscular pain}} |
|
{{Other gynecologicals}} |
|
{{Other gynecologicals}} |
|
|
{{Prostanoid signaling modulators}} |
|
] |
|
|
|
{{Portal bar | Medicine}} |
|
] |
|
|
|
{{Authority control}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|